Illustration: Brendan Lynch/Axios
Pinnacle Medicines, developer of oral peptides for immunology and cardiometabolic diseases, raised an $89 million Series B.
Why it matters: Oral peptide drugs could expand treatment options beyond injectables in large disease markets.
